Marizyme (MRZM)

Executive Summary

Marizyme Inc. is a medical technology company dedicated to preserving vascular integrity during coronary artery bypass graft (CABG) surgery. Its flagship product, DuraGraft, is an FDA-cleared solution used to flush and store saphenous vein grafts, reducing oxidative damage and improving long-term graft patency. The company addresses a critical unmet need in cardiac surgery, where graft failure remains a significant cause of morbidity and repeat procedures. Marizyme's technology has the potential to enhance patient outcomes by maintaining graft viability, thereby reducing the need for reintervention. Despite a validated product and clearance from regulators, the company faces challenges in commercial adoption, market penetration, and scaling operations. With a broad intellectual property portfolio and growing awareness of the importance of graft preservation, Marizyme is positioned to capture a share of the global CABG market. However, execution risk remains material given limited financial resources and competition from alternative graft management strategies. The company's valuation is modest relative to the opportunity, offering potential upside for investors if commercial traction accelerates.

Upcoming Catalysts (preview)

• Q3 2026Commercial launch expansion or key distribution partnership40% success
• H2 2026Publication of real-world clinical outcomes data supporting DuraGraft efficacy60% success
• Q1 2027Regulatory approval or clearance for additional indications (e.g., other vascular grafts)30% success